Market capitalization | $3.18b |
Enterprise Value | $3.04b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 19.43 |
P/S ratio (TTM) P/S ratio | 20.35 |
P/B ratio (TTM) P/B ratio | 12.04 |
Sales growth (TTM) Sales growth | 83.44% |
Turnover (TTM) Turnover | $156.33m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
9 Analysts have issued a PROCEPT BioRobotics forecast:
9 Analysts have issued a PROCEPT BioRobotics forecast:
Mar '24 | |
Current assets | 329 329 |
Fixed assets | 54 54 |
Total assets | 383 383 |
Mar '24 | |
Equity | 264 264 |
Debt capital | 119 119 |
Total capital | 383 383 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Reza Zadno |
Employees | 626 |
Founded | 2007 |
Website | www.procept-biorobotics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.